Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efmoroctocog alfa - Bioverativ/Swedish Orphan Biovitrum

Drug Profile

Efmoroctocog alfa - Bioverativ/Swedish Orphan Biovitrum

Alternative Names: Antihaemophilic factor VIII (recombinant), Fc fusion protein; BIIB-031; Efmoroctocog alfa; Efraloctocog alfa; Elocta; Eloctate; Factor VIII-Fc; FVIII-Fc; Long-lasting factor VIII fusion protein; Recombinant factor VIII Fc; Recombinant factor VIII Fc fusion protein; rFVIII-Fc

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Bioverativ; Swedish Orphan Biovitrum; Syntonix Pharmaceuticals
  • Class Blood coagulation factors; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 23 Sep 2019 Bioverativ Therapeutics completes the phase III PUPs A-LONG trial for Hemophilia A (In children, In infants, In neonates, Treatment-naive) in Australia, Brazil, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, New Zealand, Poland, Spain, Sweden, USA and United Kingdom (IV) (NCT02234323)
  • 02 Dec 2018 Final results from the phase II/III ASPIRE trial in Haemophilia A released by Orphan Biovitrum
  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top